Metabolite profiling of fecal water extracts from human colorectal cancer

NMR in Biomedicine

Volumn 22, Issue 3, 2009, Pages 342-348

  Monleón, Daniel ^a,b   Morales, José Manuel ^b   Barrasa, Antonio ^c   López, Jose Antonio ^c   Vázquez, Carlos ^c   Celda, Bernardo ^b,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

1H NMR spectroscopy; Colorectal cancer; Fecal water extracts; Metabolite profiling; Metabolomics; Metabonomics

Indexed keywords

1H NMR SPECTROSCOPY; COLORECTAL CANCER; FECAL WATER EXTRACTS; METABOLITE PROFILING; METABOLOMICS; METABONOMICS;

BIOMOLECULES; DIAGNOSIS; FATTY ACIDS; METABOLISM; METABOLITES; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

SOLVENT EXTRACTION;

ACETIC ACID; ALANINE; ARGININE; BUTYRIC ACID; CARNITINE; CITRULLINE; CYSTEINE; ETHANOLAMINE; GLUTAMIC ACID; HISTIDINE; INOSITOL; LACTIC ACID; LEUCINE; METHIONINE; MUCIN; PHENYLALANINE; PROLINE; SERINE; SHORT CHAIN FATTY ACID; THREONINE; TUMOR MARKER; VALINE; WATER;

ADULT; AGED; ARTICLE; CANCER SCREENING; CHEMOMETRIC ANALYSIS; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HUMAN; MALE; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; CASE CONTROL STUDY; CHEMISTRY; COLORECTAL TUMOR; DRUG MIXTURE; FECES; METABOLISM; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; COMPLEX MIXTURES; FECES; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; WATER;

EID: 64949194229     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1345     Document Type: Article

References (57)

1. Garfinkel L, Mushinski M. U.S. cancer incidence, mortality and survival: 1973-1996. Stat Bull Metrop Insur Co. 1999; 80(3): 23-32.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1): 8-31.
3. Cooper GS, Strange KC, Yuan Z. Colorectal cancer screening practices among primary care physicians in high-risk countries. Gastroenterology 1999; 116: A392.
4. 1989 Survey of physicians' attitudes and practices in early cancer detection. CA Cancer J Clin 1990; 40: 77-101.
5. Hakama M, Hoff G, Kronborg O, Påhlman L. Screening for colorectal cancer. Acta Oncol. 2005; 44(5): 425-439.
6. Levin B, Hess K, Johnson C. Screening for colorectal cancer. A. comparison of 3 fecal occult blood tests. Arch Intern Med 1997; 157: 970-976.
7. Mandel JS, Bond JH, Bradley M, Snover DC, Church TR, Williams S, Watt G, Schuman LM, Ederer F, Gilbertsen V. Sensitivity, specificity, and positive predictive value of the Hemoccult test in screening for colorectal cancers. Gastroenterology 1989; 97: 597-600.
8. Ahlquist DA, Gilbert J. Stool markers for colorectal cancer screening: future considerations. Dig Dis 1996; 14: 132-144.
9. Nakayama T, Yasuoka H, Kishino T, Ohguchi H, Takada M. ELISA for occult fecal albumin. Lancet 1992; I: 1368-1369.
10. Dubrow R, Yannieli L. Fecal protein markers of colorectal cancer. Am J Gastroenterol 1992; 87: 854-858.
11. Dubrow R, Kim CS, Eldred AK. Fecal lysozyme: an unreliable marker for colorectal cancer. Am J Gastroenterol 1992; 87: 617-621.
12. Hirata I, Hoshimoto M, Saito O, Kayazawa M, Nishikawa T, Murano M, Toshina K, Wang FY, Matsuse R. Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol. 2007; 13(10): 1569-1574.
13. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P. et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105.
14. Ito Y, Kobayashi S, Taniguchi T, Kainuma O, Hara T, Ochiai T. Frequent detection of K-ras mutation in stool samples of colorectal carcinoma patients after improved DNA extraction: comparison with tissue samples. Int J Oncol. 2002; 20(6): 1263-1268.
15. Smith-Ravin J, England J, Talbot IC, Bodmer W. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 1995; 36: 81-86.
16. Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, Losi L, Perini M, Trande P, Merighi A, Lerose R, Manenti F. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology. 1996; 110: 1346-1353.
17. Nollau P, Moser C, Weinland G, Wagener C. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 1996; 66: 332-336.
18. Eguchi S, Kohara N, Komuta K, Kanematsu T. Mutations of the p53 gene in stool of patients with resectable colorectal cancer. Cancer 1996; 77: 1707-1710.
19. Ahmed FE, Vos PW, Ijames S, Lysle DT, Flake G, Sinar DR, Naziri W, Marcuard SP. Standardization for transcriptomic molecular markers to screen human colon cancer. Cancer Genomics Proteomics. 2007; 4(6): 419-431.
20. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology. 2005; 128(1): 192-206.
21. Mak T, Lalloo F, Evans DG, Hill J. Molecular stool screening for colorectal cancer. Br J Surg. 2004; 91(7): 790-800.
22. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&D. FEBSJ. 2007 Mar: 274(5): 1140-1151.
23. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol. 2005; 3(5): 431-438.
24. Wang Y, Holmes E, Nicholson JK, Cloarec O, Chollet J, Tanner M, Singer BH, Utzinger J. Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci USA. 2004; 101(34): 12676-12681.
25. Walle T. Absorption and metabolism of flavonoids. Free Radic. Biol. Med. 2004; 36: 829-837.
26. Rasmussen SE, Frederiksen H, Struntze KK, Poulsen L. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol. Nutr. Food Res. 2005; 49: 159-174.
27. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&D. FEBSJ. 2007 Mar: 274(5): 1140-1151.
28. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002; 1: 153-161.
29. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B. Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J. Proteome Res. 2008; 7(7): 2882-2888.
30. Fava F, Lovegrove JA, Gitau R, Jackson KG, Tuohy KM. The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. Curr. Med. Chem. 2006; 13: 3005-3021.
31. Martínez-Granados B, Monleón D, Martínez-Bisbal MC, Rodrigo JM, del Olmo J, Lluch P, Ferrández A, Martí-Bonmatí L, Celda B. Metabolite identification in human liver needle biopsies by high-resolution magic angle spinning 1H NMR spectroscopy. NMR Biomed. 2006; 19(1): 90-100.
32. Martinez-Bisbal MC, Monleon D, Assemat O, Piotto M, Piquer J, Llácer JL, Celda B. Determination of Metabolite concentrations in human brain tumour biopsy samples using HR-MAS and ERETIC measurements. NMR Biomed 2008 Oct 2. [ONLINE AHEAD OF PRINT].
33. 1H MRS study of human high grade gliomas. NMR Biomed. 2004; 17(4): 191-205.
34. Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, Wilson ID, Wang Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res. 2007; 6(2): 546-551.
35. Saric J, Wang Y, Li J, Coen M, Utzinger J, Marchesi JR, Keiser J, Veselkov K, Lindon JC, Nicholson JK, Holmes E. Species variation in the fecal metabolome gives insight into differential gastrointestinal function. J. Proteome Res. 2008; 7(1): 352-360.
36. Jacobs DM, Deltimple N, van Velzen E, van Dorsten FA, Bingham M, Vaughan EE, van Duynhoven J. (1)H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome. NMR Biomed. 2008; 21(6): 615-626.
37. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32(9): 920-924.
38. Kim Y, Lee S, Park S, Jeon H, Lee W, Kim JK, Cho M, Kim M, Lim J, Kang CS, Han K. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci. 2003; 33(1): 32-38.
39. Verboven S, Hubert M. LIBRA: a MATLAB Library for Robust Analysis, Chemometrics and Intelligent Laboratory Systems. 2005; 75: 127-136.
40. Parsons HM, Ludwig C, Günther UL, Viant MR. Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation. BMC Bioinformatics. 2007; 8: 234.
41. 1H NMR spectra of biofluids. Analyst. 2002; 127(10): 1283-1288.
42. 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst. 2003; 128(1): 32-36.
43. Hassig CA, Tong JK, Schreiber SL. Fiber-derived butyrate and the prevention of colon cancer. Chem Biol. 1997; 4(11): 783-789.
44. Pouillart PR. Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life Sci. 1998; 63(20): 1739-1760.
45. Lim CC, Ferguson LR, Tannock GW. Dietary fibres as "prebiotics": implications for colorectal cancer. Mol Nutr Food Res. 2005; 49(6): 609-619.
46. Bingham SA. Mechanisms and experimental and epidemiological evidence relating dietary fibre (non-starch polysaccharides) and starch to protection against large bowel cancer. Proc. Nutr. Soc. 1990, 49, 153-171.
47. Boffa LC, Lupton JR, Mariani MR, Ceppi M, Newmark HL, Scalmati A, Lipkin M. Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res. 1992; 52: 5906-5912.
48. Chai F, Evdokiou A, Young GP, Zalewski PD. Involvement of p21(Waf1/ Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. Carcinogenesis 2000, 21, 7-14.
49. Domon-Dell C, Wang Q, Kim S, Kedinger M, Evers BM, Freund JN. Stimulation of the intestinal Cdx2 homeobox gene by butyrate in colon cancer cells. Gut 2002, 50, 525-529.
50. Hague A, Paraskeva C. The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Eur. J. Cancer Prev. 1995, 4, 359-364.
51. Abrahamse SL, Pool-Zobel BL, Rechkemmer G. Potential of short chain fatty acids to modulate the induction of DNA damage and changes in the intracellular calcium concentration by oxidative stress in isolated rat distal colon cells. Carcinogenesis. 1999; 20(4): 629-634.
52. Dolara P, Caderni G, Salvadori M, Morozzi G, Fabiani R, Cresci A, Orpianesi C, Trallori G, Russo A, Palli D. Fecal levels of short-chain fatty acids and bile acids as determinants of colonic mucosal cell proliferation in humans. Nutr Cancer. 2002; 42(2): 186-190.
53. Corfield AP, Carroll D, Myerscough N, Probert CSJ. Mucins in the gastrointestinal tract in health and disease. Frontiers Biosci 2001; 6: D1321-1357.
54. Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK. Structural organization and classification of the human mucin genes. Frontiers Biosci 2001; 6: D1192-1206.
55. Jass JR, Walsh MD. Altered mucin expression in the gastrointestinal tract: A review. Frontiers Gastroenterol 2001; 5: 327-351.
56. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995; 57: 607-634.
57. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004; 23(1-2): 77-99.